國家衛生研究院 NHRI:Item 3990099045/4394

NHRI > National Institute of Cancer Research > Others > Periodical Articles > Item 3990099045/4394

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4394

Title:	Comparative dosimetric evaluation of nanotargeted 188Re-(DXR)- liposome for internal radiotherapy
Authors:	Chang, CH;Stabin, MG;Chang, YJ;Chen, LC;Chen, MH;Chang, TJ;Lee, TW;Ting, G
Contributors:	National Institute of Cancer Research
Abstract:	A dosimetric analysis was performed to evaluate nanoliposomes as carriers of radionuclides (Re-188-liposomes) and radiochemotherapeutic drugs [Re-188-doxorubicin (DXR)-liposomes] in internal radiotherapy for colon carcinoma, as evaluated in mice. Methods: Pharmacokinetic data for Re-188-N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), Re-188-liposome, and Re-188-DXR-liposome were obtained for the estimation of absorbed doses in tumors and normal organs. Two colon carcinoma mouse models were employed: subcutaneous growing solid tumor and malignant ascites pervading tumor models. Radiation-dose estimates for normal tissues and tumors were calculated by using the OLINDA/EXM program. An evaluation of a recommended maximum administered activity (MAA) for the nanotargeted drugs was also made. Results: Mean absorbed closes derived from Re-188-liposome and Re-188-DXR-liposome in normal tissues were generally similar to those from Re-188-BMEDA in intraperitoneal and intravenous administration. Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively for Re-188-liposome and Re-188-DXR-liposome. Tumor-absorbed doses for the nanotargeted Re-188-liposome and Re-188-DXR-liposome were higher than those of Re-188-BMEDA for both routes of administration (4-26-fold). Dose to red marrow defined the recommended MAA. Conclusions: Our results suggest that radionuclide and chemoradiotherapeutic passive targeting delivery, using nanoliposomes as the carrier, is feasible and promising in systemic-targeted radionuclide therapy.
Date:	2008-12
Relation:	Cancer Biotherapy and Radiopharmaceuticals. 2008 Dec;23(6):749-758.
Link to:	http://dx.doi.org/10.1089/cbr.2008.0489
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1084-9785&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000262772100009
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=56249130692
Appears in Collections:	[Others] Periodical Articles

Files in This Item:

There are no files associated with this item.

Loading...